These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27814987)

  • 21. Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.
    Fang W; Gan J; Huang Y; Zhou H; Zhang L
    J Thorac Oncol; 2019 Dec; 14(12):e274-e275. PubMed ID: 31757379
    [No Abstract]   [Full Text] [Related]  

  • 22. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
    Yoshida H; Ooi M; Kim YH
    J Thorac Oncol; 2018 Nov; 13(11):e219-e220. PubMed ID: 30368410
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and Safety of Osimertinib in a Hemodialysis Patient With Advanced Non-Small Cell Lung Cancer.
    Iwafuchi Y; Saito I; Narita I
    Ther Apher Dial; 2017 Aug; 21(4):416-417. PubMed ID: 28332292
    [No Abstract]   [Full Text] [Related]  

  • 24. Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
    Li J; Wang Z; Groen HJM; Zhao J; Wang P; Zhang C; Yang K; Guo Y; Ma J
    Lung Cancer; 2018 Apr; 118():173-175. PubMed ID: 29502892
    [No Abstract]   [Full Text] [Related]  

  • 25. EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Dearden S; Brown H; Jenkins S; Thress KS; Cantarini M; Cole R; Ranson M; Jänne PA
    Lung Cancer; 2017 Jul; 109():9-13. PubMed ID: 28577957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug approval: Osimertinib as an adjuvant treatment of non-small cell lung carcinoma with EFGR mutation after complete resection].
    Chevassut D; Duchemann B
    Bull Cancer; 2021 Dec; 108(12):1072-1073. PubMed ID: 34702549
    [No Abstract]   [Full Text] [Related]  

  • 27. [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].
    Griesinger F; Radke S; Lüers A; Deschler-Baier B; Kimmich M; Sebastian M; Schulz C; Brugger W; Wiewrodt R; Pirker R; Früh M; Gautschi O; Wolf J
    Pneumologie; 2018 Nov; 72(11):774-781. PubMed ID: 30408830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
    Soejima K; Yasuda H; Hirano T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Divergent
    Rehman M; Kim C; Reuss JE; Kiedrowski LA; Garg RJ; Liu SV
    JCO Precis Oncol; 2021 Nov; 5():939-942. PubMed ID: 34994624
    [No Abstract]   [Full Text] [Related]  

  • 30. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
    Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
    Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.
    Lim JU
    Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):619-626. PubMed ID: 34364740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osimertinib for the treatment of patients with
    Alsharedi M; Bukamur H; Elhamdani A
    Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
    McCoach CE; Jimeno A
    Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
    Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).
    Watanabe H; Ichihara E; Kano H; Ninomiya K; Tanimoto M; Kiura K
    Intern Med; 2017 Aug; 56(16):2195-2197. PubMed ID: 28781309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC.
    Gourd E
    Lancet Oncol; 2018 Oct; 19(10):e516. PubMed ID: 30197172
    [No Abstract]   [Full Text] [Related]  

  • 37. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Ariyasu R; Nishikawa S; Uchibori K; Oh-Hara T; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Kitazono S; Yanagitani N; Horiike A; Inase N; Kasahara K; Nishio M; Katayama R
    Lung Cancer; 2018 Mar; 117():1-6. PubMed ID: 29496249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
    Gortais H; Daniel C; Bidard FC; Jeannot E; Callens C; Cabel L
    J Thorac Oncol; 2017 Sep; 12(9):e138-e139. PubMed ID: 28838712
    [No Abstract]   [Full Text] [Related]  

  • 39. Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.
    Makarov M; Peled N; Shochat T; Zer A; Rotem O; Dudnik E
    Isr Med Assoc J; 2019 Jun; 21(6):394-398. PubMed ID: 31280508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
    Chen CW; Kuo CW; Chen YL; Ho CL; Su WC; Lin CC
    J Thorac Oncol; 2017 Jun; 12(6):e72-e74. PubMed ID: 28532566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.